What question did this study set out to answer?

To evaluate whether 100 mg of HA-1A reduces 14-day all-cause mortality in patients with septic shock and gram-negative bacteremia, and to assess its safety in patients without bacteremia.

July 1, 1994Annals of Internal Medicine

Treatment of Septic Shock with Human Monoclonal Antibody HA-1A

View Full Paper

Ask AI

Bookmark

Authors

RMRichard V. McCloskeyJohnson & Johnson (United States)

Discussion

Member takes

Implication

Randomized double-blind trial finds no mortality reduction with HA-1A in septic shock, indicating that the antibody is ineffective for presumptive gram-negative sepsis.

Key Points

To evaluate whether 100 mg of HA-1A reduces 14-day all-cause mortality in patients with septic shock and gram-negative bacteremia, and to assess its safety in patients without bacteremia.
Randomized, double-blind, multicenter, placebo-controlled trial conducted across 513 hospitals in the United States enrolling 2,199 patients in septic shock with presumptive gram-negative infection.
Patients received either 100 mg of HA-1A or placebo within 24 hours of shock onset, with blood cultures obtained within 48 hours and 14-day mortality tracked as the primary outcome.
Among 621 patients with confirmed gram-negative bacteremia, 14-day mortality was 33% (109 of 328) with HA-1A compared to 32% (95 patients) with placebo (P=0.864; 95% CI for the difference, -6.2% to 8.6%).
Among patients without gram-negative bacteremia, 14-day mortality was 41% (318 of 785) with HA-1A compared to 37% (292 of 793) with placebo (P=0.073; 95% CI for the difference, -0.8% to 8.8%).

Cite This Study

Richard V. McCloskey (1994) studied this question.

synapsesocial.com/papers/6a8514da2efc34c14b847e7c https://doi.org/10.7326/0003-4819-121-1-199407010-00001

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial finds no mortality reduction with HA-1A in septic shock, indicating that the antibody is ineffective for presumptive gram-negative sepsis.

Treatment of Septic Shock with Human Monoclonal Antibody HA-1A

Discussion

Member takes

Implication

Key Points

Cite This Study

Treatment of Septic Shock with Human Monoclonal Antibody HA-1A

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider